Atlas Trials

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

Clinical trial NCT00615602 · COMPLETED

Trial details

NCT number
NCT00615602
Sponsor
Hellenic Oncology Research Group
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2004-10-01
Primary completion
2012-05-01
Enrollment
489

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.